Publications by authors named "V Bono"
Article Synopsis
- A study assessed how long COVID-19 antibodies last in 93 people with HIV after receiving an mRNA booster vaccination.
- Researchers explored the impact of T-cell dysfunction and certain aging-related biomarkers on the duration of these antibody responses.
- They discovered that specific immune cell ratios and characteristics (like a low CD4/CD8 ratio) are linked to quicker declines in antibody levels, enhancing our understanding of immune responses in HIV patients after vaccination.
Article Synopsis
- - Cefiderocol, a new antibiotic, is effective against carbapenem-resistant Gram-negative bacteria but lacks real-world usage data concerning therapy types and patient demographics.
- - A study of 200 cases found that cefiderocol was primarily used as targeted therapy (72.5%) rather than empirical (27.5%) and was administered equally as monotherapy (50.5%) and in combination (49.5%).
- - The findings highlight that specific patient histories, like previous infections and conditions, influence the choice between monotherapy and combination therapy, emphasizing the need for better guidelines and further studies on treatment efficacy.
Introduction: We compared the effectiveness and virological clearance (VC) at day 7 (T7) post-treatment with molnupiravir, nirmatrelvir/ritonavir, and remdesivir in SARS-CoV-2-infected patients at high risk (HR) for clinical progression.
Methods: We conducted a retrospective study enrolling HR patients with mild-to-moderate COVID-19 (Jan-Oct 2022) treated with nirmatrelvir/ritonavir or molnupiravir or 3 days of remdesivir. We investigated clinical recovery at T7 (resolution of symptoms for ≥ 72 h or all-cause death), VC at T7 (PCR/antigenic negative nasopharyngeal swab), and median time to VC (days from symptom onset to the first negative swab).
Background: HIV-associated neurocognitive disorders (HAND) still affects persons with HIV (PWH) and their pathogenesis is not completely understood. We aimed to explore the association between plasma and cerebrospinal fluid (CSF) markers of blood-brain barrier (BBB) impairment and HAND in untreated PWH.
Design: Cross-sectional study.
Article Synopsis
- The study focused on comparing hospitalized vaccinated and non-vaccinated patients diagnosed with SARS-CoV-2 in three major hospitals in Northern Italy, investigating their clinical characteristics and outcomes.
- Data analysis highlighted that vaccinated patients, despite having more serious underlying health issues, generally had milder COVID-19 symptoms and required less intensive care compared to non-vaccinated patients.
- No significant difference in intra-hospital mortality rates was found between the two groups, indicating vaccination effectively reduces the likelihood of ICU admission but does not significantly impact overall survival rates in the hospital.